Abstract
The purpose of this study was to investigate the effect of probenecid, an inhibitor of the MRP2/ ABCC transporter, on the pharmacokinetics and transport of belotecan (7-[2-(N-isopropy-lamino)ethyl]-(20S)-camptothecin). The effect of probenecid on the pharmacokinetics of belotecan was studied in rats. When belotecan was injected as a bolus dose of 5 mg/kg after probenecid was infused at a rate of 42.8 mg/2 mL/h/kg, the cumulative biliary excretion amounts and biliary clearance (CLb) of belotecan decreased (28.29 ±2.83 versus 19.96 ± 1.45% of dose and 161.01 ± 26.95 versus 92.66 ± 1.45 mL/min/kg), whereas the systemic pharmacokinetics did not change. This indicates that the MRP2 transporter is involved in the biliary excretion of belotecan. The involvement of MRP2 in the secretory transport was further characterized using Caco-2 cell monolayers expressing MRP2. The apparent permeability across Caco-2 cell monolayers from basolateral to apical was 2.3 times greater than that from the apical to the basolateral side at the 50 μM belotecan. In addition, probenecid significantly decreased the basolateral-to-apical transport of belotecan (52.9%). These results indicate that MRP2 is involved in the secretory transport of belotecan in biliary excretion.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Artursson, P. and Karlsson, J., Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells.Biochem. Biophys. Res. Commun., 175, 880–885 (1991).
Cho, J. Y., Seo, H. B., Yu, K. S., Bae, K. S., Yi, S. Y., Jang, I. J., and Shin, S. G., Simple and sensitive determination of the new anti-tumor drug CKD-602 in human plasma by liquid chromatography.J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 784, 25–31 (2003).
Chu, X. Y., Kato, Y., Niinuma, K., Sudo, K. I., Hakusui, H., and Sugiyama, Y., Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.J. Pharmacol. Exp. Then, 281, 304–314 (1997a).
Chu, X. Y., Kato, Y., and Sugiyama, Y., Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.Cancer Res., 57,1934–1938 (1997b).
Chu, X. Y., Kato, Y., Ueda, K., Suzuki, H., Niinuma, K., Tyson, C. A., Weizer, V., Dabbs, J. E., Froehlich, R., Green, C. E., and Sugiyama, Y., Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.Cancer Res., 58, 5137–5143 (1998).
Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., and Ratain, M. J., Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.Cancer Res., 54, 3723–3725(1994).
Horikawa, M., Kato, Y., and Sugiyama, Y., Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.Pharm. Res., 19,1345–1353(2002).
Jew, S. S., Kim, M. G., Kim, H. J., Rho, E. Y., Park, H. G., Kim, J. K., Han, H. J., and Lee, H., Synthesis and in vitro cytotoxicity of C(20)(RS)-camptothecin analogues modified at both B (or A) and E ring.Bioorg. Med. Chem. Lett., 8, 1797–1800 (1998).
Kim, R., Hirabayashi, N., Nishiyama, M., Jinushi, K., Toge, T., and Okada, K., Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice.Int. J. Cancer., 50, 760–766 (1992).
Lee, J. H., Lee, J. M., Kim, J. K., Ahn, S. K., Lee, S. J., Kim, M. Y., Jew, S. S., Park, J. G., and Hong, C. I., Anti-tumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.Arch. Pharm. Res., 21, 581–590 (1998).
Lee, J. H., Lee, J. M., Lim, K. H., Kim, J. K., Ahn, S. K., Bang, Y. J., and Hong, C. I., Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative.Ann. N Y Acad. Sci., 922, 324–325 (2000).
Li, H., Chung, S. J., Kim, D. C., Kim, H. S., Lee, J. W., and Shim, C. K., The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4- tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers.Drug Metab. Dispos., 29, 54–59(2001).
Ohno, R., Yoshida, Y., Oguro, M., Ogawa, M., Sakai, Y., Furue, H., Ariyoshi, Y., Saito, H., Masaoka, T., Kimura, I.et al., [An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with hematological malignancies].Gan To Kagaku Ryoho., 21, 75–82 (1994).
Prime-Chapman, H. M., Fearn, R. A., Cooper, A. E., Moore, V., and Hirst, B. H., Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells.J. Pharmacol. Exp. Then, 311,476–484 (2004).
Sha, X. and Fang, X., Transport characteristics of 9-nitrocamp- tothecin in the human intestinal cell line Caco-2 and everted gut sacs.Int J Pharm., 272,161–171 (2004).
Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H., The current status of camptothecin analogues as anti-tumor agents.J. Natl. Cancer Inst., 85, 271–291 (1993).
Taipalensuu, J., Tornblom, H., Lindberg, G., Einarsson, C., Sjoqvist, F., Melhus, H., Garberg, P., Sjostrom, B., Lundgren, B., and Artursson, P., Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers.J. Pharmacol. Exp. Ther., 299,164–170(2001).
Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi, T., and Kamataki, T., Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the anti-tumor agent, irinotecan hydrochloride (CPT-11) in rats.Cancer Chemother. Pharmacol., 42,280–286(1998).
Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi, T., and Kamataki, T., Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the anti-tumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.Cancer Res., 56, 3752–3757 (1996).
Takasuna, K., Kasai, Y., Kitano, Y., Mori, K., Kakihata, K., Hirohashi, M., and Nomura, M., [Study on the mechanisms of diarrhea induced by a new anti-cancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats].Nippon Yakurigaku Zasshi., 105,447–460 (1995).
Tanizawa, A., Fujimori, A., Fujimori, Y., and Pommier, Y., Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.J. Natl. Cancer Inst., 86, 836–842 (1994).
Vali, A. M., Shafaghi, B., and Dadashzadeh, S., Simple and sensitive high performance liquid Chromatographic method for the simultaneous quantitation of the lactone and car- boxylate forms of topotecan in human plasma.J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 818,205–212 (2005).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Namkoong, EM., Kim, IW., Kim, DD. et al. Effect of probenecid on the biliary excretion of belotecan. Arch Pharm Res 30, 1482–1488 (2007). https://doi.org/10.1007/BF02977375
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02977375